Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, Z. Y.
Right arrow Articles by Henquin, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, Z. Y.
Right arrow Articles by Henquin, J. C.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 42, Issue 6 914-921, Copyright © 1993 by American Diabetes Association

ARTICLES

Arginine vasopressin and oxytocin effects in mouse pancreatic beta-cells. Receptors involved in stimulation of insulin release

ZY Gao and JC Henquin
Unit of Diabetes and Nutrition, University of Louvain, Faculty of Medicine, Brussels, Belgium.

Recently AVP and OT were suggested to increase insulin release by stimulating phosphoinositide metabolism in pancreatic beta-cells. In this study, mouse islets were used to identify the receptors involved in the effects of AVP and OT. Both agents caused concentration-dependent (0.1 nM to 10 microM) increases in insulin release and IP levels. The potencies of AVP and OT were similar, and their maximal effects were not additive. Synthetic agonists selective for AVP (V1) and OT receptors in other tissues were equipotent with the natural agonists on insulin release and almost equipotent on IPs. Antagonists selective for V1 and OT receptors inhibited both types of effects with a potency that varied with the nature of the agonist. Both AVP and OT were approximately 10-fold potent on insulin release (EC50 approximately 2 nM) than on IPs (EC50 approximately 25 nM). Moreover, the antagonists more readily inhibited the effects of all agonists on IPs than on insulin release. Pancreatic beta-cells may possess either a single type of receptor that is distinct from classic V1 or OT receptors, but is closer to the latter, or both V1 and OT receptors coupled to common effectors. The acceleration of phosphoinositide turnover might not be the sole mechanism involved in the stimulation of insulin release by AVP and OT.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, and A. Tanoue
Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice
J. Endocrinol., February 1, 2007; 192(2): 361 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Oshikawa, A. Tanoue, T.-a. Koshimizu, Y. Kitagawa, and G. Tsujimoto
Vasopressin Stimulates Insulin Release from Islet Cells through V1b Receptors: a Combined Pharmacological/Knockout Approach
Mol. Pharmacol., March 1, 2004; 65(3): 623 - 629.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1993 by the American Diabetes Association.